SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Diagnostic value of S100P for pancreatic cancer: a meta-analysis.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of novel biomarkers in the early diagnosis of pancreatic cancer: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Novel quantitative analysis of the S100P protein combined with endoscopic ultrasound-guided fine needle aspiration cytology in the diagnosis of pancreatic adenocarcinoma.Oncology reports · 2017Trial
- Article
- A Novel Diagnostic Model of Biomarkers in the Washing Fluid Obtained by EUS-FNA in Pancreatic Cancer.Journal of gastrointestinal cancer · 2025Article
- The road to overcome pancreatic cancer: Where are we?Heliyon · 2024Review
- Diagnosis and prognosis of pancreatic cancer with immunoglobulin heavy constant delta blood marker.Journal of cancer research and clinical oncology · 2023Article
- S100s and HMGB1 Crosstalk in Pancreatic Cancer Tumors.Biomolecules · 2023Article
- Bioinformatics-based construction of prognosis-related methylation prediction model for pancreatic cancer patients and its application value.Frontiers in pharmacology · 2023Article
- Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma.Scientific reports · 2022Article
- Friend or Foe: S100 Proteins in Cancer.Cancers · 2020Review
- PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression.BMC cancer · 2020Article
- Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer.Medicine · 2019Article
- Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.Neoplasia (New York, N.Y.) · 2019Article
- Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors.Frontiers in pharmacology · 2018Review
- Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma.Frontiers in genetics · 2018Article
- The life and works of S100P - from conception to cancer.American journal of cancer research · 2016Review
- The role of S100 proteins and their receptor RAGE in pancreatic cancer.Biochimica et biophysica acta · 2015Review
- Molecular detection of pancreatic neoplasia: Current status and future promise.World journal of gastroenterology · 2015Review
- S100P interacts with integrin α7 and increases cancer cell migration and invasion in lung cancer.Oncotarget · 2015Article
- The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.Molecular cancer research : MCR · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a fatal disease with a high mortality and poor prognosis. PC is the fourth leading cause of cancer death in America, and 80 % of PCs are diagnosed at an unresectable stage. Effective early detection assays are crucial since a successful operation at early stage is the best strategy for this disease. S100 calcium-binding protein P (S100P) has been reported as a predictive diagnostic index for PC and involves in the development of PC. However, the diagnostic accuracy of S100P in detecting PC has never been systematically assessed. The aim of the present study was to evaluate the diagnostic performance of S100P for PC. All relevant original articles about S100P in the diagnosis of PC published up to December 2013 were retrieved. The methodological quality of each study was assessed by QUADAS. The overall diagnostic sensitivity, specificity, diagnostic odds ratio (DOR), with 95 % confidence interval (CI), and area under the receiver operating characteristic curve (AUC) were pooled to evaluate the diagnostic value of S100P for PC using the Meta-DiSc1.4 statistical software. Eight studies met our criteria in the present meta-analysis. The pooled sensitivity, specificity, and DOR calculated by the bivariate random effects model were 0.87 (95 % CI 0.83-0.90), 0.88 (95 % CI 0.82-0.93), and 38.32 (95 % CI 11.22-130.87), respectively. The summary receiver operating characteristic (SROC) curve was located near the desirable left corner and the AUC was 0.9272. The current evidence suggests that S100P plays an important role in the diagnosis of PC with a high sensitivity and specificity. S100P may be regarded as a promising diagnostic marker to PC screening.
Indexed as
Identifiers
25123266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.